Background: Cognitive enhancers, including cholinesterase inhibitors and memantine, are
used to treat dementia, but their effectiveness for mild cognitive impairment is unclear. We …

Background Mild cognitive impairment (MCI) refers to a transitional zone between normal
ageing and dementia. Despite the uncertainty regarding the definition of MCI as a clinical …

BackgroundMore people are presenting with mild cognitive impairment (MCI), frequently a
precursor to dementia, but we do not know how to reduce deterioration. AimsTo …

Background: The clinical benefit of cholinesterase inhibitors (ChEIs) for mild cognitive
impairment (MCI) remains inconclusive. Objective: We performed a systematic review and …

Background: The effectiveness of treatments for mild cognitive impairment is uncertain. The
aim of this review was to evaluate the effectiveness and harms of treatment for mild cognitive …

Background The use of cholinesterase inhibiors for Alzheimer's disease (AD) is currently
being appraised by the National Institute for Clintical Evidence (NICE). This article provides …

Background Problems with memory which do not meet the diagnostic criteria for dementia,
usually called mild cognitive impairment (MCI), can be the first sign of an impending …

Background: The effectiveness of the 5 US Food and Drug Administration–approved
pharmacologic therapies for dementias in achieving clinically relevant improvements is …

Background: The role of currently available drugs for Alzheimer's disease (AD) has been
controversial, with some national formularies restricting their use, and health economists …

Background Individual randomized clinical trials (RCTs) with cholinesterase inhibitors
(ChEIs) aiming to delay the progression from mild cognitive impairment (MCI) to Alzheimer's …